肿瘤新抗原预测与鉴定的研究进展

Advances in prediction and identification of tumor neoantigens

肿瘤新抗原是肿瘤免疫治疗的特异性靶标,具有高度异质性。如何准确且快速地鉴定肿瘤新抗原是其应用于临床肿瘤免疫治疗的关键,目前仍处于早期开发阶段且具有挑战性。根据基因组测序、转录组测序或表位肽质谱数据、并结合计算工具评估免疫原性是肿瘤新抗原预测和鉴定的基本方法。

Tumor neoantigens are specific targets for tumor immunotherapy,but they are highly heterogeneous.Accurate prediction and identification of tumor neoantigens are a premise for individualized tumor-specific immunotherapy based on neoantigens.A fundamental method for tumor neoantigen prediction and identification is based on wholeexon sequencing,transcriptome sequencing,or epitope mass spectrometry combined with computational tools to assess immunogenicity.In recent years,new progress has been made to more precisely predict and identify various types of neoantigens.This review summarized recent development of based-on multi-omics sequencing,T-cell receptor epitope screening and comprehensive bioinformatic prediction pipelines,and immunogenicity identification methods,to promote development of new technologies for neoantigen-based tumor immunotherapy and improve clinical immunotherapy efficacy.